CL
Celon Pharma S.A.
CLN.WA · WSE
21.75 zł +0.23% (+0.05 zł)
1M +4.58%
Market Cap 1.19B zł
P/E Ratio 10.97x
Div. Yield -
ROE 26.07%
Piotroski F-Score Moderate
5/9Valuation
78 /100
Cheap P/S 5.42x
P/B 2.25x
P/E 10.97x
Growth
49 /100
Stable Book val. growth 8.85%
Rev. growth 9.02%
FCF growth N/A
Profitability
30 /100
Weak FCF margin 15.75%
Op. margin 11.93%
Gross margin 27.76%
Quality
49 /100
Average Asset turnover 0.33x
ROA 16.19%
ROIC 3.93%
Debt
58 /100
Moderate Current ratio 1.20x
Int. coverage -12.99x
Debt/Equity 0.10x
Stability
39 /100
Moderate Profitable years 0
EPS volatility 77.25%
Beta 0.63x
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o CLN.WA
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Maciej Wieczorek
Employees
564
Headquarters
Lomianki